CIK 0001104506 · Large accelerated filer
INSMED Inc
Sign in to watch- Ticker
- INSM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- VA
- Entity type
- operating
- EIN
- 541972729
- Phone
- 908-977-9900
- Business address
- 700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,737,650
- in 2 filings
Net −$3,737,650. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Sale 10b5-1 | −31,030 | $174.28 | $5.4M | 98,014 |
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Sale 10b5-1 | −34,103 | $175.17 | $6.0M | 63,911 |
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Sale 10b5-1 | −12,832 | $176.08 | $2.3M | 51,079 |
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Sale 10b5-1 | −9,125 | $177.17 | $1.6M | 41,954 |
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Sale 10b5-1 | −200 | $177.78 | $36K | 41,754 |
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Grant or award · Stock Option (right to buy) 10b5-1 | +27,600 | 27,600 | ||
| 2026-01-02 | Schaeffer Orlov S Nicole Chief People Strategy Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −87,290 | 0 | ||
| 2025-12-18 | Lewis William Chair and CEO | Option exercise 10b5-1 | +4,440 | $17.16 | $76K | 308,351 |
| 2025-12-18 | Lewis William Chair and CEO | Option exercise 10b5-1 | +6,259 | $30.46 | $191K | 314,610 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −350 | $162.26 | $57K | 314,260 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −1,465 | $163.19 | $239K | 312,795 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −447 | $164.24 | $73K | 312,348 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −697 | $165.21 | $115K | 311,651 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −1,783 | $166.60 | $297K | 309,868 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −1,431 | $167.29 | $239K | 308,437 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −2,175 | $168.54 | $367K | 306,262 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −1,938 | $169.58 | $329K | 304,324 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −362 | $170.26 | $62K | 303,962 |
| 2025-12-18 | Lewis William Chair and CEO | Sale 10b5-1 | −51 | $171.20 | $9K | 303,911 |
| 2025-12-18 | Lewis William Chair and CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −4,440 | 62,160 |
Page 13 of 23 · 448 trades